Investor Overview

Corporate Profile
Verastem, Inc. (NASDAQ: VSTM) is a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR and Wnt.
Stock Quote
VSTM (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$9.59
Change (%) Stock is Up 0.63 (7.03%)
Volume401,691
Data as of 10/24/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News More >>
DateTitle 
10/24/14Verastem Presents New Data on Mesothelioma Programs at the 12th International Mesothelioma Interest Group Meeting
-Results from a Window of Opportunity study in surgically-eligible patients demonstrate a reduction in pFAK, cancer stem cell markers and tumor size following 12 days of treatment with VS-6063- BOSTON--(BUSINESS WIRE)--Oct. 24, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the presentation of clinical and preclinical data in oral presenta... 
Printer Friendly Version
10/08/14Verastem to Present New Data at the 12th International Mesothelioma Interest Group Conference
NEEDHAM, Mass.--(BUSINESS WIRE)--Oct. 8, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that it will present new data at the 12th International Mesothelioma Interest Group (iMig) Conference being held October 22-24, 2014, in Cape Town, South Africa. Investigators and members of the Verastem leadership team will give oral presenta... 
Printer Friendly Version
08/07/14Verastem Reports Second Quarter 2014 Financial and Corporate Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 7, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, reported financial results for the second quarter ended June 30, 2014, and also provided an overview of certain corporate accomplishments and plans. “We ended the second quarter with a cash, cash equivalents and investments balance of $104.4 million which w... 
Printer Friendly Version
07/10/14Verastem Presents Results and Updated Development Plans at Annual Research and Development Day
-Lead cancer stem cell inhibitor VS-6063 continues to show promise in the clinic- -An additional partial response reported since ASCO in the combination trial of VS-6063 and paclitaxel in ovarian cancer- -64% stable disease or better as best clinical response to date, including five objective responses, in the ongoing combination trial of VS-6063 and paclitaxel in ovarian cancer- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 10, 2014... 
Printer Friendly Version
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Verastem Inc posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.